New drug combo shows promise in advanced breast cancer trial
NCT ID NCT03964532
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a two-step treatment for advanced breast cancer that cannot be cured with surgery or radiation. First, patients receive a drug called talazoparib alone, then both talazoparib and avelumab together. The main goal is to check safety and side effects, while also exploring how the drugs affect the immune system. About 24 adults with measurable tumors are participating.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple